Is semaglutide good for your heart? The evidence, plainly explained

The SELECT trial: what happened and who was in it

The cardiovascular case for semaglutide rests largely on the SELECT trial, a large randomised study involving over 17,000 adults who had overweight or obesity (BMI 27 or above) and established cardiovascular disease (a previous heart attack, stroke, or peripheral artery disease) but who did not have type 2 diabetes. Participants received either 2.4mg semaglutide weekly or a placebo, alongside standard care, for around four years on average.

The result: those on semaglutide had a roughly 20% lower risk of a major cardiovascular event (specifically the composite of heart attack, stroke or cardiovascular death) compared with those on placebo. That is a statistically robust finding across the trial population, and it prompted the MHRA to grant a cardiovascular risk reduction indication for Wegovy in the UK. The full detail of this cardiovascular authorisation is worth reading if you want the regulatory picture.

One detail that attracted particular clinical interest: the benefit appeared early and persisted even in participants who lost relatively little weight. That suggests the medicine may reduce cardiovascular risk through pathways beyond calorie deficit alone, possibly through anti-inflammatory effects or direct cardiovascular actions of GLP-1 receptor agonism. The research is still active on exactly why.

The NHS summarises semaglutide's evidence base, indications and cautions on its medicines information page for semaglutide, a useful baseline before any clinical conversation.

Who the cardiovascular indication applies to, and who it does not

The cardiovascular licence is specific. It applies to adults aged 45 and over with a BMI of 27 or above who have established cardiovascular disease, defined as a prior heart attack, prior stroke or prior peripheral artery disease. People who simply have cardiovascular risk factors (high blood pressure, high cholesterol, a family history) but no previous event do not fall within the SELECT-derived indication.

It also does not cover every kind of heart condition. Heart failure with preserved or reduced ejection fraction, arrhythmias, or structural valve disease are separate clinical territories. The cardiovascular authorisation addresses major adverse events in a well-defined population; it is not a blanket cardiac medicine.

For most people reading this page, the more immediately relevant question is the weight-management licence (BMI of 30 or above, or 27 to 29.9 with a weight-related condition) which runs alongside the cardiovascular one. If you sit within the SELECT population, a prescriber will weigh both indications when assessing your suitability. You can read how the cardiovascular indication is considered for people already managing heart conditions if that applies to you.

Separately, semaglutide's effects on heart rate are worth a brief mention: some people notice a modest increase in resting heart rate, typically within a normal range. This is covered in more detail on the page about semaglutide and heart rate changes, worth a look if that is on your mind.

The practical decision: weight management, cardiovascular risk, or both?

If you are weighing up whether semaglutide is appropriate for your cardiovascular situation, the decision has a few distinct strands. First: are you within the eligible weight-management population? Second: do you have the established cardiovascular disease history that the SELECT trial enrolled? Third: are there any conditions in your history (recent acute coronary syndrome, active heart failure, certain arrhythmias) that warrant extra clinical caution?

None of those questions can be answered responsibly without seeing your full picture. That is not a bureaucratic hurdle; it reflects how the trial evidence was designed. A prescriber who reviews your medical history, current medications and relevant test results is doing what the evidence asks of them.

It is also worth thinking about timing in a practical sense. Many people come to this decision after a difficult health event, a diagnosis, a scan result, a conversation with a GP around a routine appointment. There is rarely a neutral moment. If you are ready to start the conversation, our free consultation connects you with a GPhC-registered prescriber the same day, and the assessment covers your cardiovascular history as part of a full clinical picture.

Cost is a real consideration too. Anyone researching private treatment can find out what a legitimate Wegovy prescription involves and what an honest price includes, consultation, clinical review and aftercare are not optional extras in a safe service.

Side effects relevant to heart health, and when to act

Most side effects with semaglutide are gastrointestinal: nausea, loose stools, constipation, and occasionally vomiting, particularly in the first weeks or after a dose step. These matter in a cardiovascular context because significant vomiting or diarrhoea can cause dehydration, which places extra demand on the heart and kidneys. Staying hydrated and letting your clinical team know if GI symptoms are severe is sensible practice rather than optional advice.

The modest increase in resting heart rate mentioned above is usually clinically insignificant, but people with rhythm disorders should raise this explicitly with their prescriber before starting.

Anyone on semaglutide who experiences chest pain, shortness of breath, or symptoms of stroke (facial droop, arm weakness, speech difficulty) should call 999 immediately. These are not semaglutide side effects to wait out; they are emergencies. The Yellow Card scheme at yellowcard.mhra.gov.uk allows patients to report suspected side effects directly to the MHRA, which is useful if you notice something unexpected.

If pregnancy is part of your future planning alongside cardiovascular treatment, the interaction between semaglutide and pregnancy and conception carries its own guidance that is worth reading separately.